S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
NASDAQ:BRTX

BioRestorative Therapies (BRTX) Stock Price, News & Analysis

$1.50
+0.10 (+7.14%)
(As of 03/1/2024 ET)
Today's Range
$1.43
$1.57
50-Day Range
$1.28
$3.45
52-Week Range
$1.20
$7.13
Volume
380,897 shs
Average Volume
1.37 million shs
Market Capitalization
$7.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BioRestorative Therapies MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of BioRestorative Therapies in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$163,770 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.47) to ($2.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars


BRTX stock logo

About BioRestorative Therapies Stock (NASDAQ:BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BRTX Stock Price History

BRTX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/03/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:BRTX
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
$-18,500,000.00
Net Margins
-12,195.10%
Pretax Margin
-12,194.34%

Debt

Sales & Book Value

Annual Sales
$120,000.00
Book Value
$4.34 per share

Miscellaneous

Free Float
3,690,000
Market Cap
$7.07 million
Optionable
Not Optionable
Beta
61.93
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Lance Alstodt (Age 53)
    Chairman of the Board, President & CEO
    Comp: $400k
  • Mr. Robert Eugene Kristal (Age 56)
    Chief Financial Officer
    Comp: $175k
  • Mr. Francisco J. Silva (Age 49)
    Chief Scientist, VP of Research & Development, Secretary and Director
    Comp: $375k
  • Mr. Robert Paccasassi (Age 55)
    Vice President of Quality Assurance & Regulatory Compliance
    Comp: $233.95k
  • Dr. Wayne J. Olan M.D.
    Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board














BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed in 2024?

BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTX shares have decreased by 13.8% and is now trading at $1.50.
View the best growth stocks for 2024 here
.

Are investors shorting BioRestorative Therapies?

BioRestorative Therapies saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 73,500 shares, an increase of 260.3% from the January 31st total of 20,400 shares. Based on an average daily volume of 436,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 2.1% of the company's shares are short sold.
View BioRestorative Therapies' Short Interest
.

When is BioRestorative Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our BRTX earnings forecast
.

Who are BioRestorative Therapies' major shareholders?

BioRestorative Therapies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.56%). Insiders that own company stock include Dale Broadrick, Francisco Silva and Lance Alstodt.
View institutional ownership trends
.

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BRTX) was last updated on 3/3/2024 by MarketBeat.com Staff